Genetic Basis of Alopecia Areata. A Roadmap for Translational Research

Dermatologic Clinics

Volumn 31, Issue 1, 2013, Pages 109-117

  Jabbari, Ali ^a   Petukhova, Lynn ^a   Cabral, Rita M ^a   Clynes, Raphael ^a   Christiano, Angela M ^a  

^a Columbia University ^*  (United States)

Author keywords

Alopecia areata; Autoimmune disease; Genetic; Translational research

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; ABATACEPT; BELATACEPT; CORTICOSTEROID; CYCLOSPORIN; DIPHENCYPRONE; DITHRANOL; MINOXIDIL;

ALOPECIA AREATA; AUTOIMMUNE DISEASE; CHROMOSOME 10P; CHROMOSOME 11Q; CHROMOSOME 12Q; CHROMOSOME 16P; CHROMOSOME 2Q; CHROMOSOME 4Q; CHROMOSOME 5Q; CHROMOSOME 6P; CHROMOSOME 6Q; CHROMOSOME 9Q; CLINICAL FEATURE; CTLA 4 GENE; DISEASE ASSOCIATION; DRUG DEVELOPMENT; DRUG TARGETING; GENE; GENE IDENTIFICATION; GENETIC ASSOCIATION; HAIR LOSS; HUMAN; IL2 GENE; IL21 GENE; IL2RA GENE; LINKAGE ANALYSIS; MOLECULAR GENETICS; NONHUMAN; PATHOGENESIS; PHOTODYNAMIC THERAPY; PREVALENCE; PRIORITY JOURNAL; REVIEW; ULBP3 GENE; ULBP6 GENE; UNITED STATES;

ALOPECIA AREATA; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HAIR FOLLICLE; HUMANS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84869159610     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2012.08.014     Document Type: Review

References (91)

1. Hon K.L., Leung A.K. Alopecia areata. Recent Pat Inflamm Allergy Drug Discov 2011, 5:98.
2. Safavi K. Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey. Arch Dermatol 1992, 128:702.
3. Safavi K.H., Muller S.A., Suman V.J., et al. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 1995, 70:628.
4. Tan E., Tay Y.K., Goh C.L., et al. The pattern and profile of alopecia areata in Singapore-a study of 219 Asians. Int J Dermatol 2002, 41:748.
5. Tan E., Tay Y.K., Giam Y.C. A clinical study of childhood alopecia areata in Singapore. Pediatr Dermatol 2002, 19:298.
6. Barahmani N., Schabath M.B., Duvic M. History of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol 2009, 61:581.
7. Muller S.A., Winkelmann R.K. Alopecia areata. An evaluation of 736 patients. Arch Dermatol 1963, 88:290.
8. Shellow W.V., Edwards J.E., Koo J.Y. Profile of alopecia areata: a questionnaire analysis of patient and family. Int J Dermatol 1992, 31:186.
9. Wang S.J., Shohat T., Vadheim C., et al. Increased risk for type I (insulin-dependent) diabetes in relatives of patients with alopecia areata (AA). Am J Med Genet 1994, 51:234.
10. Friedmann P.S. Alopecia areata and auto-immunity. Br J Dermatol 1981, 105:153.
11. Cunliffe W.J., Hall R., Stevenson C.J., et al. Alopecia areata, thyroid disease and autoimmunity. Br J Dermatol 1969, 81:877.
12. Corazza G.R., Andreani M.L., Venturo N., et al. Celiac disease and alopecia areata: report of a new association. Gastroenterology 1995, 109:1333.
13. Rzhetsky A., Wajngurt D., Park N., et al. Probing genetic overlap among complex human phenotypes. Proc Natl Acad Sci U S A 2007, 104:11694.
14. Cunliffe W.J., Hall R., Newell D.J., et al. Vitiligo, thyroid disease and autoimmunity. Br J Dermatol 1968, 80:135.
15. Narita T., Oiso N., Fukai K., et al. Generalized vitiligo and associated autoimmune diseases in Japanese patients and their families. Allergol Int 2011, 60(4):505-508.
16. Sipetic S., Vlajinac H., Kocev N., et al. Family history and risk of type 1 diabetes mellitus. Acta Diabetol 2002, 39:111.
17. Petukhova L., Duvic M., Hordinsky M., et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 2010, 466:113.
18. Ghersetich I., Campanile G., Lotti T. Alopecia areata: immunohistochemistry and ultrastructure of infiltrate and identification of adhesion molecule receptors. Int J Dermatol 1996, 35:28.
19. Todes-Taylor N., Turner R., Wood G.S., et al. T cell subpopulations in alopecia areata. J Am Acad Dermatol 1984, 11:216.
20. Gregoriou S., Papafragkaki D., Kontochristopoulos G., et al. Cytokines and other mediators in alopecia areata. Mediators Inflamm 2010, 2010:928030.
21. Brajac I., Kastelan M., Perisa D., et al. Lijec Vjesn 2010, 132:365. [in Croatian].
22. Jelinek J.E. Sudden whitening of the hair. Bull N Y Acad Med 1972, 48:1003.
23. Wasserman D., Guzman-Sanchez D.A., Scott K., et al. Alopecia areata. Int J Dermatol 2007, 46:121.
24. Delamere F.M., Sladden M.M., Dobbins H.M., et al. Interventions for alopecia areata. Cochrane Database Syst Rev 2008, (2). CD004413.
25. Mitchell A.J., Balle M.R. Alopecia areata. Dermatol Clin 1987, 5:553.
26. Blaumeiser B., van der Goot I., Fimmers R., et al. Familial aggregation of alopecia areata. J Am Acad Dermatol 2006, 54:627.
27. McDonagh A.J., Tazi-Ahnini R. Epidemiology and genetics of alopecia areata. Clin Exp Dermatol 2002, 27:405.
28. van der Steen P., Traupe H., Happle R., et al. The genetic risk for alopecia areata in first degree relatives of severely affected patients. An estimate. Acta Derm Venereol 1992, 72:373.
29. Jackow C., Puffer N., Hordinsky M., et al. Alopecia areata and cytomegalovirus infection in twins: genes versus environment?. J Am Acad Dermatol 1998, 38:418.
30. Scerri L., Pace J.L. Identical twins with identical alopecia areata. J Am Acad Dermatol 1992, 27:766.
31. Colombe B.W., Lou C.D., Price V.H. The genetic basis of alopecia areata: HLA associations with patchy alopecia areata versus alopecia totalis and alopecia universalis. J Investig Dermatol Symp Proc 1999, 4:216.
32. de Andrade M., Jackow CM., Dahm N., et al. Alopecia areata in families: association with the HLA locus. J Investig Dermatol Symp Proc 1999, 4:220.
33. Sundberg J.P., Silva K.A., Li R., et al. Adult-onset alopecia areata is a complex polygenic trait in the C3H/HeJ mouse model. J Invest Dermatol 2004, 123:294.
34. Gilhar A., Paus R., Kalish R.S. Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest 2007, 117:2019.
35. Martinez-Mir A., Zlotogorski A., Gordon D., et al. Genomewide scan for linkage reveals evidence of several susceptibility loci for alopecia areata. Am J Hum Genet 2007, 80:316.
36. Jagielska D., Redler S., Brockschmidt F.F., et al. Follow-up study of the first genome-wide association scan in alopecia areata: IL13 and KIAA0350 as susceptibility loci supported with genome-wide significance. J Invest Dermatol 2012, 132(9):2192-2197.
37. John K.K., Brockschmidt F.F., Redler S., et al. Genetic variants in CTLA4 are strongly associated with alopecia areata. J Invest Dermatol 2011, 131:1169.
38. Gregersen P.K., Amos C.I., Lee A.T., et al. REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. Nat Genet 2009, 41:820.
39. Stahl E.A., Raychaudhuri S., Remmers E.F., et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 2010, 42:508.
40. Barrett J.C., Clayton D.G., Concannon P., et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 2009, 41:703.
41. Cooper J.D., Smyth D.J., Smiles A.M., et al. Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. Nat Genet 2008, 40:1399.
42. Dubois P.C., Trynka G., Franke L., et al. Multiple common variants for celiac disease influencing immune gene expression. Nat Genet 2010, 42:295.
43. Parrish-Novak J., Dillon S.R., Nelson A., et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000, 408:57.
44. Parrish-Novak J., Foster D.C., Holly R.D., et al. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol 2002, 72:856.
45. Hinrichs C.S., Spolski R., Paulos C.M., et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 2008, 111:5326.
46. Champsaur M., Lanier L.L. Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2010, 235:267.
47. Ito T., Ito N., Saatoff M., et al. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol 2008, 128:1196.
48. Gambelunghe G., Brozzetti A., Ghaderi M., et al. MICA gene polymorphism in the pathogenesis of type 1 diabetes. Ann N Y Acad Sci 2007, 1110:92.
49. Kirsten H., Petit-Teixeira E., Scholz M., et al. Association of MICA with rheumatoid arthritis independent of known HLA-DRB1 risk alleles in a family-based and a case control study. Arthritis Res Ther 2009, 11:R60.
50. Fernandez-Morera J.L., Rodriguez-Rodero S., Tunon A., et al. Genetic influence of the nonclassical major histocompatibility complex class I molecule MICB in multiple sclerosis susceptibility. Tissue Antigens 2008, 72:54.
51. Li Y., Xia B., Lu M., et al. MICB0106 gene polymorphism is associated with ulcerative colitis in central China. Int J Colorectal Dis 2010, 25:153.
52. Rodriguez-Rodero S., Rodrigo L., Fdez-Morera J.L., et al. MHC class I chain-related gene B promoter polymorphisms and celiac disease. Hum Immunol 2006, 67:208.
53. Martin J.E., Carmona F.D., Broen J.C., et al. The autoimmune disease-associated IL2RA locus is involved in the clinical manifestations of systemic sclerosis. Genes Immun 2012, 13(2):191-196.
54. Lindner E., Weger M., Steinwender G., et al. IL2RA gene polymorphism rs2104286 A>G seen in multiple sclerosis is associated with intermediate uveitis: possible parallel pathways?. Invest Ophthalmol Vis Sci 2011, 52:8295.
55. Lowe C.E., Cooper J.D., Brusko T., et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet 2007, 39:1074.
56. Maier L.M., Anderson D.E., Severson C.A., et al. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol 2009, 182:1541.
57. Carr E.J., Clatworthy M.R., Lowe C.E., et al. Contrasting genetic association of IL2RA with SLE and ANCA-associated vasculitis. BMC Med Genet 2009, 10:22.
58. Alcina A., Fedetz M., Ndagire D., et al. IL2RA/CD25 gene polymorphisms: uneven association with multiple sclerosis (MS) and type 1 diabetes (T1D). PLoS One 2009, 4:e4137.
59. Makis A.C., Galanakis E., Hatzimichael E.C., et al. Serum levels of soluble interleukin-2 receptor alpha (sIL-2Ralpha) as a predictor of outcome in brucellosis. J Infect 2005, 51:206.
60. Giordano C., Galluzzo A., Marco A., et al. Increased soluble interleukin-2 receptor levels in the sera of type 1 diabetic patients. Diabetes Res 1988, 8:135.
61. Greenberg P., Klarnet J., Kern D., et al. Requirements for T cell recognition and elimination of retrovirally-transformed cells. Princess Takamatsu Symp 1988, 19:287.
62. Hill J.A., Feuerer M., Tash K., et al. Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. Immunity 2007, 27:786.
63. Pan F., Yu H., Dang E.V., et al. Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science 2009, 325:1142.
64. Entz P., Blaumeiser B., Betz R.C., et al. Investigation of the HLA-DRB1 locus in alopecia areata. Eur J Dermatol 2006, 16:363.
65. Elias J.A., Lee C.G. IL-13 in asthma. The successful integration of lessons from mice and humans. Am J Respir Crit Care Med 2011, 183:957.
66. Li X., Howard T.D., Zheng S.L., et al. Genome-wide association study of asthma identifies RAD50-IL13 and HLA-DR/DQ regions. J Allergy Clin Immunol 2010, 125:328.
67. Chang M., Li Y., Yan C., et al. Variants in the 5q31 cytokine gene cluster are associated with psoriasis. Genes Immun 2008, 9:176.
68. Nair R.P., Duffin K.C., Helms C., et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009, 41:199.
69. van den Berg L.M., Gringhuis S.I., Geijtenbeek T.B. An evolutionary perspective on C-type lectins in infection and immunity. Ann N Y Acad Sci 2012, 1253:149.
70. Barahmani N., Lopez A., Babu D., et al. Serum T helper 1 cytokine levels are greater in patients with alopecia areata regardless of severity or atopy. Clin Exp Dermatol 2010, 35(4):409-416.
71. Hafler D.A., Compston A., Sawcer S., et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007, 357:851.
72. Hakonarson H., Grant S.F., Bradfield J.P., et al. A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene. Nature 2007, 448:591.
73. Wellcome Trust Case Control Consortium Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447:661.
74. Kropotov A., Serikov V., Suh J., et al. Constitutive expression of the human peroxiredoxin V gene contributes to protection of the genome from oxidative DNA lesions and to suppression of transcription of noncoding DNA. FEBS J 2006, 273:2607.
75. Kubo E., Singh D.P., Fatma N., et al. TAT-mediated peroxiredoxin 5 and 6 protein transduction protects against high-glucose-induced cytotoxicity in retinal pericytes. Life Sci 2009, 84:857.
76. Ding Y., Yamada S., Wang K.Y., et al. Overexpression of peroxiredoxin 4 protects against high-dose streptozotocin-induced diabetes by suppressing oxidative stress and cytokines in transgenic mice. Antioxid Redox Signal 2010, 13:1477.
77. Franke A., McGovern D.P., Barrett J.C., et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010, 42:1118.
78. Sundstrom E., Komisarczuk A.Z., Jiang L., et al. Identification of a melanocyte-specific, microphthalmia-associated transcription factor-dependent regulatory element in the intronic duplication causing hair greying and melanoma in horses. Pigment Cell Melanoma Res 2012, 25:28.
79. Rosengren Pielberg G., Golovko A., Sundstrom E., et al. A cis-acting regulatory mutation causes premature hair graying and susceptibility to melanoma in the horse. Nat Genet 2008, 40:1004.
80. Karopka T., Fluck J., Mevissen H.T., et al. The Autoimmune Disease Database: a dynamically compiled literature-derived database. BMC Bioinformatics 2006, 7:325.
81. Linsley P.S., Greene J.L., Tan P., et al. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med 1992, 176:1595.
82. Tan R., Teh S.J., Ledbetter J.A., et al. B7 costimulates proliferation of CD4-8+ T lymphocytes but is not required for the deletion of immature CD4+8+ thymocytes. J Immunol 1992, 149:3217.
83. Knoerzer D.B., Karr R.W., Schwartz B.D., et al. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J Clin Invest 1995, 96:987.
84. Pearson T.C., Alexander D.Z., Hendrix R., et al. CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model. Evidence for hematopoietic chimerism. Transplantation 1996, 61:997.
85. Ndejembi M.P., Teijaro J.R., Patke D.S., et al. Control of memory CD4 T cell recall by the CD28/B7 costimulatory pathway. J Immunol 2006, 177:7698.
86. Finck B.K., Linsley P.S., Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994, 265:1225.
87. Khoury S.J., Akalin E., Chandraker A., et al. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol 1995, 155:4521.
88. Kremer J.M., Dougados M., Emery P., et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005, 52:2263.
89. Abrams J.R., Lebwohl M.G., Guzzo C.A., et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999, 103:1243.
90. Carroll J.M., McElwee K.J., E King L., et al. Gene array profiling and immunomodulation studies define a cell-mediated immune response underlying the pathogenesis of alopecia areata in a mouse model and humans. J Invest Dermatol 2002, 119:392.
91. Sundberg J.P., McElwee K.J., Carroll J.M., et al. Hypothesis testing: CTLA4 co-stimulatory pathways critical in the pathogenesis of human and mouse alopecia areata. J Invest Dermatol 2011, 131:2323.